Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Decellularized Dermis ECM-Based Melanoma-on-a-Chip Model with Integrated Lymphatic and Vascular Networks for High-Throughput Drug Testing

Vázquez-Aristizabal P., Arriola-Alvarez I., Henriksen-Lacey M., Alonso-Martin S., van den Broek L., Liz-Marzán LM.

Laboratory Study on Hip, published in ACS Appl Bio Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
ACS Appl Bio Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41708064
PMCID
PMC12997241
DOI
10.1021/acsabm.5c02329

Abstract (original English)

Developing effective treatments for malignant melanoma remains a complex challenge, requiring models that accurately replicate the tumor microenvironment to study metastasis and drug response. Whereas in vitro models have become essential tools due to their tunability and controllability, systems incorporating both biomimetic extracellular matrices (ECM) and vascular components are more complex and therefore remain challenging. In this study, we present an in vitro melanoma model comprising a dermal decellularized ECM (dECM) together with both blood and lymphatic vessels, cultured within a commercial microfluidic platform that enables high-throughput testing. Our system features a triculture melanoma spheroid embedded within a dermis dECM hydrogel and flanked by vascular structures, effectively recreating key aspects of the melanoma microenvironment, as confirmed by immunostaining for canonical markers and morphological resemblance. Proof-of-concept drug testing demonstrates the model's suitability for high-throughput drug screening, as validated by cytotoxicity assays. The complexity and biomimetic nature of this model provides a robust platform for studying melanoma progression, tumor-vascular interactions, and therapeutic responses, ultimately offering a promising alternative for in vitro melanoma research and drug development.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Extracellular MatrixLymphatic VesselsDermisHumansMelanomaAntineoplastic AgentsBiocompatible MaterialsDrug Screening Assays, AntitumorMaterials TestingLab-On-A-Chip Devices

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research